The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
Panelists discuss how prospective randomized data, notably from Hofman et al (Lancet, 2020), demonstrate that PSMA PET-CT exhibits superior diagnostic accuracy compared with conventional imaging in detecting pelvic nodal and distant metastases in patients with high-risk prostate cancer. Conventional imaging techniques, such as CT and bone scans, often have lower sensitivity and specificity, potentially missing smaller or early metastatic lesions. In contrast, PSMA PET-CT offers enhanced sensitivity and specificity, leading to more precise staging and management decisions.
EP: 1.The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
EP: 2.PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
EP: 3.Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
EP: 4.Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
EP: 5.PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
EP: 6.PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
EP: 7.Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
EP: 8.Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
EP: 9.Utilizing PSMA PET Imaging in Metastatic Prostate Cancer to Guide Treatment Strategies
EP: 10.Case Discussion: Integrating PSMA PET for Focal Boost Optimization
EP: 11.Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
EP: 12.Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Video content above is prompted by the following:
- What have prospective randomized data shown when comparing conventional vs PSMA-PET imaging, and how have these data influenced the current landscape? (Hofman et al. Lancet. 2020)
- What are some of the key limitations of conventional imaging techniques, and what key advantages does PSMA PET provide over conventional imaging?
- Briefly comment on the current NCCN guidelines regarding preferred imaging approaches in the diagnosis and management of prostate cancer. (NCCN Clinical Guidelines in Oncology. Prostate cancer, version 1.2025)
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
